| Jeannette M Sorace-burton, NP | |
|
251 Main St, Exeter, RI 02822-3531 | |
| (888) 671-9392 | |
| Not Available |
| Full Name | Jeannette M Sorace-burton |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 251 Main St, Exeter, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780063628 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southcoast Hospitals Group | Fall river, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southcoast Physicians Group Inc | 0749171957 | 746 |
| The Providence Center Inc | 9739080292 | 45 |
News Archive
Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.
There's little question that most kids get too little calcium, but a new review of evidence casts doubt on the value of supplements and calcium-fortified foods to build stronger bones.
MedeAnalytics, a leading provider of healthcare performance management solutions, today announced its latest release of the company's Patient Access Intelligence solution, which streamlines the front-end registration and financial clearance process for healthcare providers. The release incorporates client input and reflects the company's strategic vision to address the entire revenue cycle of patient financial care, from registration to billing.
Traumatic brain injury (TBI) is a major cause of mortality and morbidity, often causing lifelong disability for those who survive. Treatment is limited to supportive care, but stem cell therapy has received recent attention as a way to promote recovery for injuries to the central nervous system (CNS). In this study, researchers transplanted human neural stem cells (hNSCs) into the brains of mice modeled with TBI to investigate whether the hosts' immune systems and the stem cells acting in concert would enhance repair.
› Verified 7 days ago
| Entity Name | Community Counseling Of Bristol County, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730215781 PECOS PAC ID: 0143127779 Enrollment ID: O20040917000246 |
News Archive
Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.
There's little question that most kids get too little calcium, but a new review of evidence casts doubt on the value of supplements and calcium-fortified foods to build stronger bones.
MedeAnalytics, a leading provider of healthcare performance management solutions, today announced its latest release of the company's Patient Access Intelligence solution, which streamlines the front-end registration and financial clearance process for healthcare providers. The release incorporates client input and reflects the company's strategic vision to address the entire revenue cycle of patient financial care, from registration to billing.
Traumatic brain injury (TBI) is a major cause of mortality and morbidity, often causing lifelong disability for those who survive. Treatment is limited to supportive care, but stem cell therapy has received recent attention as a way to promote recovery for injuries to the central nervous system (CNS). In this study, researchers transplanted human neural stem cells (hNSCs) into the brains of mice modeled with TBI to investigate whether the hosts' immune systems and the stem cells acting in concert would enhance repair.
› Verified 7 days ago
| Entity Name | Southcoast Physicians Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336137629 PECOS PAC ID: 0749171957 Enrollment ID: O20040920000138 |
News Archive
Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.
There's little question that most kids get too little calcium, but a new review of evidence casts doubt on the value of supplements and calcium-fortified foods to build stronger bones.
MedeAnalytics, a leading provider of healthcare performance management solutions, today announced its latest release of the company's Patient Access Intelligence solution, which streamlines the front-end registration and financial clearance process for healthcare providers. The release incorporates client input and reflects the company's strategic vision to address the entire revenue cycle of patient financial care, from registration to billing.
Traumatic brain injury (TBI) is a major cause of mortality and morbidity, often causing lifelong disability for those who survive. Treatment is limited to supportive care, but stem cell therapy has received recent attention as a way to promote recovery for injuries to the central nervous system (CNS). In this study, researchers transplanted human neural stem cells (hNSCs) into the brains of mice modeled with TBI to investigate whether the hosts' immune systems and the stem cells acting in concert would enhance repair.
› Verified 7 days ago
| Entity Name | The Commonwealth Of Massachusetts |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194803288 PECOS PAC ID: 8820906860 Enrollment ID: O20040928000190 |
News Archive
Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.
There's little question that most kids get too little calcium, but a new review of evidence casts doubt on the value of supplements and calcium-fortified foods to build stronger bones.
MedeAnalytics, a leading provider of healthcare performance management solutions, today announced its latest release of the company's Patient Access Intelligence solution, which streamlines the front-end registration and financial clearance process for healthcare providers. The release incorporates client input and reflects the company's strategic vision to address the entire revenue cycle of patient financial care, from registration to billing.
Traumatic brain injury (TBI) is a major cause of mortality and morbidity, often causing lifelong disability for those who survive. Treatment is limited to supportive care, but stem cell therapy has received recent attention as a way to promote recovery for injuries to the central nervous system (CNS). In this study, researchers transplanted human neural stem cells (hNSCs) into the brains of mice modeled with TBI to investigate whether the hosts' immune systems and the stem cells acting in concert would enhance repair.
› Verified 7 days ago
| Entity Name | The Commonwealth Of Massachusetts |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326155458 PECOS PAC ID: 8820906860 Enrollment ID: O20050203000148 |
News Archive
Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.
There's little question that most kids get too little calcium, but a new review of evidence casts doubt on the value of supplements and calcium-fortified foods to build stronger bones.
MedeAnalytics, a leading provider of healthcare performance management solutions, today announced its latest release of the company's Patient Access Intelligence solution, which streamlines the front-end registration and financial clearance process for healthcare providers. The release incorporates client input and reflects the company's strategic vision to address the entire revenue cycle of patient financial care, from registration to billing.
Traumatic brain injury (TBI) is a major cause of mortality and morbidity, often causing lifelong disability for those who survive. Treatment is limited to supportive care, but stem cell therapy has received recent attention as a way to promote recovery for injuries to the central nervous system (CNS). In this study, researchers transplanted human neural stem cells (hNSCs) into the brains of mice modeled with TBI to investigate whether the hosts' immune systems and the stem cells acting in concert would enhance repair.
› Verified 7 days ago
| Entity Name | New England Center For Psychiatric And Addiction Disorders Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154713030 PECOS PAC ID: 7911213764 Enrollment ID: O20150825004022 |
News Archive
Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.
There's little question that most kids get too little calcium, but a new review of evidence casts doubt on the value of supplements and calcium-fortified foods to build stronger bones.
MedeAnalytics, a leading provider of healthcare performance management solutions, today announced its latest release of the company's Patient Access Intelligence solution, which streamlines the front-end registration and financial clearance process for healthcare providers. The release incorporates client input and reflects the company's strategic vision to address the entire revenue cycle of patient financial care, from registration to billing.
Traumatic brain injury (TBI) is a major cause of mortality and morbidity, often causing lifelong disability for those who survive. Treatment is limited to supportive care, but stem cell therapy has received recent attention as a way to promote recovery for injuries to the central nervous system (CNS). In this study, researchers transplanted human neural stem cells (hNSCs) into the brains of mice modeled with TBI to investigate whether the hosts' immune systems and the stem cells acting in concert would enhance repair.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeannette M Sorace-burton, NP 44 Grinnell Ave, Tiverton, RI 02878-1902 Ph: (781) 234-4981 | Jeannette M Sorace-burton, NP 251 Main St, Exeter, RI 02822-3531 Ph: (888) 671-9392 |
News Archive
Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.
There's little question that most kids get too little calcium, but a new review of evidence casts doubt on the value of supplements and calcium-fortified foods to build stronger bones.
MedeAnalytics, a leading provider of healthcare performance management solutions, today announced its latest release of the company's Patient Access Intelligence solution, which streamlines the front-end registration and financial clearance process for healthcare providers. The release incorporates client input and reflects the company's strategic vision to address the entire revenue cycle of patient financial care, from registration to billing.
Traumatic brain injury (TBI) is a major cause of mortality and morbidity, often causing lifelong disability for those who survive. Treatment is limited to supportive care, but stem cell therapy has received recent attention as a way to promote recovery for injuries to the central nervous system (CNS). In this study, researchers transplanted human neural stem cells (hNSCs) into the brains of mice modeled with TBI to investigate whether the hosts' immune systems and the stem cells acting in concert would enhance repair.
› Verified 7 days ago
Nicholas Michael Minior, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 251 Main St, Exeter, RI 02822 Phone: 855-430-9439 |